0 CHECKOUT

Gastroesophageal (GE) Junction Carcinomas - Pipeline Review, H2 2015

  • ID: 3446805
  • September 2015
  • 125 pages
  • Global Markets Direct
1 of 3

Gastroesophageal (GE) Junction Carcinomas - Pipeline Review, H2 2015

Summary

The report ‘Gastroesophageal (GE) Junction Carcinomas - Pipeline Review, H2 2015’, provides an overview of the Gastroesophageal (GE) Junction Carcinomas’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Gastroesophageal (GE) Junction Carcinomas, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gastroesophageal (GE) Junction Carcinomas and special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. READ MORE >

Note: Product cover images may vary from those shown
2 of 3

List of Tables

List of Figures

Introduction

REPORT COVERAGE

Gastroesophageal (GE) Junction Carcinomas Overview

Therapeutics Development

Pipeline Products for Gastroesophageal (GE) Junction Carcinomas - Overview

Pipeline Products for Gastroesophageal (GE) Junction Carcinomas - Comparative Analysis

Gastroesophageal (GE) Junction Carcinomas - Therapeutics under Development by Companies

Gastroesophageal (GE) Junction Carcinomas - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Gastroesophageal (GE) Junction Carcinomas - Products under Development by Companies

Gastroesophageal (GE) Junction Carcinomas - Companies Involved in Therapeutics Development

Amgen Inc.

Aslan Pharmaceuticals Pte. Ltd.

AstraZeneca Plc

Basilea Pharmaceutica AG

Bristol-Myers Squibb Company

Celltrion, Inc.

Exelixis, Inc.

GlaxoSmithKline Plc

Hetero Drugs Limited

Merck & Co., Inc.

Merck KGaA

NantKwest, Inc.

Ono Pharmaceutical Co., Ltd.

Sorrento Therapeutics, Inc.

Gastroesophageal (GE) Junction Carcinomas - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

afuresertib hydrochloride - Drug Profile

Product Description

Mechanism of Action

R&D Progress

AMG-211 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

avelumab - Drug Profile

Product Description

Mechanism of Action

R&D Progress

BAL-101553 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

cabozantinib s-malate - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Cell Therapy to Target HER2 for Oncology - Drug Profile

Product Description

Mechanism of Action

R&D Progress

DKN-01 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

FS-102 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

gefitinib - Drug Profile

Product Description

Mechanism of Action

R&D Progress

haNK Program - Drug Profile

Product Description

Mechanism of Action

R&D Progress

ipilimumab - Drug Profile

Product Description

Mechanism of Action

R&D Progress

MK-2206 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

nimotuzumab - Drug Profile

Product Description

Mechanism of Action

R&D Progress

nivolumab - Drug Profile

Product Description

Mechanism of Action

R&D Progress

trastuzumab biosimilar - Drug Profile

Product Description

Mechanism of Action

R&D Progress

trastuzumab biosimilar - Drug Profile

Product Description

Mechanism of Action

R&D Progress

varlitinib - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Gastroesophageal (GE) Junction Carcinomas - Recent Pipeline Updates

Gastroesophageal (GE) Junction Carcinomas - Dormant Projects

Gastroesophageal (GE) Junction Carcinomas - Discontinued Products

Gastroesophageal (GE) Junction Carcinomas - Product Development Milestones

Featured News & Press Releases

Feb 06, 2012: Aslan Pharma Receives KFDA And IRB Grants Approval To Initiate Phase IIa Study Of ASLAN001 At Seoul National University

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Gastroesophageal (GE) Junction Carcinomas, H2 2015

Number of Products under Development for Gastroesophageal (GE) Junction Carcinomas - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Comparative Analysis by Late Stage Development, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Comparative Analysis by Early Stage Development, H2 2015

Products under Development by Companies, H2 2015

Products under Development by Companies, H2 2015 (Contd..1)

Gastroesophageal (GE) Junction Carcinomas - Pipeline by Amgen Inc., H2 2015

Gastroesophageal (GE) Junction Carcinomas - Pipeline by Aslan Pharmaceuticals Pte. Ltd., H2 2015

Gastroesophageal (GE) Junction Carcinomas - Pipeline by AstraZeneca Plc, H2 2015

Gastroesophageal (GE) Junction Carcinomas - Pipeline by Basilea Pharmaceutica AG, H2 2015

Gastroesophageal (GE) Junction Carcinomas - Pipeline by Bristol-Myers Squibb Company, H2 2015

Gastroesophageal (GE) Junction Carcinomas - Pipeline by Celltrion, Inc., H2 2015

Gastroesophageal (GE) Junction Carcinomas - Pipeline by Exelixis, Inc., H2 2015

Gastroesophageal (GE) Junction Carcinomas - Pipeline by GlaxoSmithKline Plc, H2 2015

Gastroesophageal (GE) Junction Carcinomas - Pipeline by Hetero Drugs Limited, H2 2015

Gastroesophageal (GE) Junction Carcinomas - Pipeline by Merck & Co., Inc., H2 2015

Gastroesophageal (GE) Junction Carcinomas - Pipeline by Merck KGaA, H2 2015

Gastroesophageal (GE) Junction Carcinomas - Pipeline by NantKwest, Inc., H2 2015

Gastroesophageal (GE) Junction Carcinomas - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2015

Gastroesophageal (GE) Junction Carcinomas - Pipeline by Sorrento Therapeutics, Inc., H2 2015

Assessment by Monotherapy Products, H2 2015

Number of Products by Stage and Target, H2 2015

Number of Products by Stage and Mechanism of Action, H2 2015

Number of Products by Stage and Route of Administration, H2 2015

Number of Products by Stage and Molecule Type, H2 2015

Gastroesophageal (GE) Junction Carcinomas Therapeutics - Recent Pipeline Updates, H2 2015

Gastroesophageal (GE) Junction Carcinomas - Dormant Projects, H2 2015

Gastroesophageal (GE) Junction Carcinomas - Discontinued Products, H2 2015

List of Figures

Number of Products under Development for Gastroesophageal (GE) Junction Carcinomas, H2 2015

Number of Products under Development for Gastroesophageal (GE) Junction Carcinomas - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Assessment by Monotherapy Products, H2 2015

Number of Products by Top 10 Targets, H2 2015

Number of Products by Stage and Top 10 Targets, H2 2015

Number of Products by Top 10 Mechanism of Actions, H2 2015

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015

Number of Products by Top 10 Routes of Administration, H2 2015

Number of Products by Stage and Top 10 Routes of Administration, H2 2015

Number of Products by Top 10 Molecule Types, H2 2015

Number of Products by Stage and Top 10 Molecule Types, H2 2015

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown

PURCHASING OPTIONS

HAVE A QUESTION?

EMAIL US VIEW FAQs

Our Clients

  • Photocure ASA
  • Roche Diagnostics Ltd.
  • Abbott Laboratories Ltd.
  • Pfizer Inc.
  • Novartis AG
  • Becton, Dickinson and Company (BD)